A Prospective, Multicenter, Single-arm MAC-PD Cohort: a NTM-NET and ESGMYC Collaborative Study

Eligibility Criteria

• * Newly diagnosed MAC-PD (primary or recurrent) as per the international NTM guideline that requires three-drug antimycobacterial treatment
• * Signed and dated informed consent
• * The participant is in poor general condition where participation in the study cannot be accepted per discretion of the Investigator
• * The participant has a known or suspected, current drug or alcohol abuse, that is, in the opinion of the Investigator, sufficient to compromise the safety or cooperation of the patient
• * HIV-infection;
• * Cystic fibrosis;
• * \>1 month antibiotic treatment for current MAC infection;
• * \< 6 months between previous antimycobacterial NTM-PD treatment and antimycobacterial treatment for current MAC-PD
• * Disseminated MAC infection;
• * Active pulmonary tuberculosis, fungal or nocardial disease requiring treatment;
• * Active pulmonary malignancy (primary or metastatic) or any other malignancy requiring chemotherapy or radiotherapy within 6 months before screening or anticipated during the study period;